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The radioprotective ef  fects of an acute ad  min  is  tra  tion of the isoflavone genistein (4¢,
5, 7-trihydroxyflavone), have been in  ves  ti  gated in the pres  ent study. Male mice were
ad  min  is  tered with dif  fer  ent doses (100, 200, 300, and 400 mg/kg body weight) of
genistein 24 hours prior to 8 Gy gamma ir  ra  di  a  tion and the 200 mg/kg dose of
genistein was de  ter  mined to of  fer the max  i  mum sur  viv  abil  ity and was used as an op  ti  -
mum dose for fur  ther ex  per  i  men  ta tion. The 0.5 ml dose of genistein (200 mg/kg) was
ad min is tered intraperitoneally to 2 dif fer ent groups of mice, 15 min utes and 24 hours
prior to gamma ir  ra  di  a  tion. In the mice treated with genistein with the op  ti  mum dose
24 hours be  fore ir  ra  di  a  tion, a sig  nif  i  cant in  crease in 30 day sur  vival has been re  corded
in con  trast to the mice treated with genistein 15 min  utes be  fore the ir  ra  di  a  tion. The
lon ger  sur viv abil ity  (i. e. 20% for a pe  riod of more than 30 days) has been ob  served in
the 24 hour group as com pared to that of 15 min utes (i. e. 20% for 22 days). Al  though
the radioprotective ef  fect of genistein was ev  i  dent in both groups, it was of greater
mag ni tude in the group with a lon ger in ter val, in di cat  ing thereby an ef  fi cacy with lon  -
ger  re ten tion  with  the  pos si ble  min i mum  tox ic ity,  un like  hith erto  known  other
radioprotective agents.
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IN TRO DUC TION
The radioprotective agents need to be used to
min i mize  or  pre vent  the  dam age  from  so lar  ra di a tion
ex po sure  ex pe ri enced  by  as tro nauts,  pi lots,  other  flight
per  son  nel, and fre  quent fli  ers. The radioprotective
agents can also be uti  lized for pro  tec  tion from ac  ci  den  -
tal  ra di a tion  ex po sure  caused  by  nu clear  power  fa cil i -
ties, other ra di a tion gen er at ing fa cil i ties in clud ing those 
for food ir  ra  di  a  tion, or by a det  o  na  tion of an atomic
bomb or other de  vice that re  leases ra  di  a  tion. Also, they
can be used to con  fer pro  tec  tion to the per  son  nel in  -
volved in clean  ing up the ar  eas of such ra  di  a  tion ac  ci  -
dents or dis  posal fa  cil  i  ties. The radioprotective agents
of the pres  ent dis  cov  ery are also of use in re  duc  ing the
toxic ef fects of in haled or in gested radionuclides and in
re duc ing tox ic ity caused by ra di a tion pro duced by elec -
tronic  de vices  of  non-ion iz ing na ture  of  ra di a tion,  such
as  cel lu lar  tele phones  and  mi cro waves.  Rap idly  grow -
ing interventional  ra dio log i cal  pro ce dures  such as di la -
ta  tion of stenosed ves  sels or recanalization or vas  cu  -
lar-angio-anas  to  mo  ses would also ben  e  fit from the use
of radioprotectors. Hence, there is a ne  ces  sity to search
for a radioprotector that could have mul  ti  di  men  sional
ad  van  tages. The pres  ent in  ven  tion is aimed to the pro  -
tec  tion of nor  mal cells and tis  sues in a mam  mal from
ther a peu tic  or  di ag nos tic  ra di a tion  ex po sure  by  ad min -
is  tra  tion of an isoflavone com  pound. This en  ables
larger, more ef  fec  tive doses of ra  di  a  tion to be given to
the pa  tient.
Genistein, an isoflavone found in soy, has been re  -
ported to have weak es  tro  genic and antiestrogenic prop  -
er  ties, to be an an  ti  ox  i  dant, to in  hibit topoisomerase II
and angiogenesis, and to in  duce cell dif  fer  en  ti  a  tion.
Genistein (4¢, 5, 7-trihydroxyflavone), a nat u rally oc cur -
ring isoflavone found in soy beans, has gained in creas ing
at ten tion be cause of its as so ci a tion with ben e fi cial ef fects 
in treat  ment of car  dio  vas  cu  lar dis  eases, high blood pres  -
sure, os teo po ro sis, breast can cer, and pros tate can cer [1].
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not de grade its per for mance. Nat u rally oc cur ring di etary
com po nents  also  of fer  op por tu ni ties  for  de vel op ment  as
ef  fec  tive chemopreventive and radioprotective agents
be  cause of their po  ten  tial low tox  ic  ity [2, 3]. It is spec  u  -
lated that breast can  cer pro  tec  tion in Asian women con  -
sum ing  a  tra di tional  soy con  tain  ing diet is de  rived from
early ex  po  sure to soy  bean prod ucts  con tain ing  genistein
[4]. Re  cently, Hyunki and col  lab  o  ra  tors [5] have ob  -
served the an  ti  bac  te  rial ac  tiv  ity of the soy isoflavone
genistein, which is found to block the in  va  sion of patho  -
genic  bac te ria  in  mam ma lian  ep i the lial  cells.  The  di rect
ef fect of genistein was stud ied in the sur vival and growth
of the probiotic Lactobacillus reuteri and se lected op por -
tu nis tic  bac te ria  in vi  tro as a pre  lude to in vivo use for
man  ag  ing postirradiation sep  sis. Their re  sults dem  on  -
strated the in vi tro antimicrobial ac tiv ity of genistein and
sug  gested the use of genistein in com  bi  na  tion with
probiotics, which may aug  ment the ef  fec  tive  ness of
antimicrobial ther  a  pies, cur  rently used in the man  age  -
ment of in  fec  tions, in  clud  ing those in  duced by ion  iz  ing
ir ra di a tion.
Genistein is also clas  si  fied as a phytoestrogen, a
plant de  rived nonsteroidal com  pound that pos  sesses es  -
tro gen  like  bi o log i cal  ac tiv ity.  Genistein  and  its
glycosides are mainly found in le gumes, such as Glycine
max (soy beans) and Cicer arietinum (chick  peas). Soy
beans and soy foods are the ma  jor di  etary sources of
these sub  stances [6]. Genistein has been found to have a
num ber of an ti ox i dant ac tiv i ties. It is a scav en ger of re ac -
tive ox  y  gen spe  cies and in  hib  its lipid peroxidation. It
also in  hib  its superoxide an  ion gen  er  a  tion by the en  zyme
xanthine  oxidase.  In  ad di tion,  in  an i mal  ex per i ments,
genistein has been found to in  crease the ac  tiv  i  ties of the
an ti ox i dant  en zymes  superoxide  dismutase,  glutathione
peroxidase, catalase, and glutathione reductase [7-10].
Keep ing  in  mind  the  fore go ing  ob ser va tions,  the
pos  si  bil  ity of its ef  fi  cacy as radioprotective agent can  -
not be ruled out. Hence, the pres ent study deals with the
ef  fect of genistein in ir  ra  di  ated mice vis-à-vis its re  ten  -
tion in the body.
MA TE RI ALS  AND  METH ODS
Male Swiss al  bino mice (6-8 week old) were se  -
lected from an in  bred col  ony and main  tained on stan  -
dard mouse feed (Hindustan Le  ver Ltd., New Delhi)
and wa  ter ad labitum. Mice were main  tained at con  -
stant  tem per a ture  (22  ± 1 °C) and light (12L:12D).
Genistein, ob  tained from L. C. Lab  o  ra  to  ries, New
Boston St., USA, was used 100-400 mg/kg body
weight 0.5 ml, intraperitoneally (IP). Genistein was
ad  min  is  tered 15 min  utes and 24 hours be  fore gamma
ir ra di a tion. The an i mals were ex posed to 8 Gy gamma
ra di a tion dose of Co balt-60 at the rate of 1.02 Gy/min.
The  ex per i ment  was  per formed  in  fol low ing
phases.
Phase 1. Sep a rate groups of mice were used to as -
sess the acute tox  ic  ity of genistein in non-ir  ra  di  ated
mice. Once an ac  cept  able non  toxic dose of genistein
was de  ter  mined, radioprotection stud  ies were per  -
formed. To de  ter  mine the most ef  fec  tive and op  ti  mal
dose of genistein, the male mice were ad min is tered with 
dif  fer  ent doses (100, 200, 300, and 400 mg/kg body
weight) of genistein 24 hours prior to 8 Gy of gamma ir -
ra di a tion  and the dose at which  max i mum  sur viv abil ity
oc  curred was se  lected as an op  ti  mum dose.
Phase 2. For test  ing the genistein ef  fi  cacy
against ra di a tion, male mice were di vided into fol low -
ing groups of 10 mice each:
· Group 1: Con  trol group (only ir  ra  di  ated),
· Group 2: Dimethyl sulphoxide (DMSO) sol  vent
treated  group (24 hours prior to ir  ra  di  a  tion),
· Group 3: Genistein treated  group (15 min  utes prior
to  ir ra di a tion),  and
· Group 4: Genistein treated  group (24 hours prior to
ir ra di a tion).
Mice were ad  min  is  tered IP a sin  gle in  jec  tion of
genistein of a dose of 200 mg/kg body weight 15 min utes
and 24 hours prior to a le  thal dose of gamma ra  di a tion (8
Gy of Co balt-60 at 1.02 Gy/min). The 0.5 ml dose of sol -
vent (group 2) and genistein (in sol  vent) were ad  min  is  -
tered  IP to the groups 3 and 4 be  fore gamma ir  ra  di  a  tion.
The an  i  mals were ob  served for their sur  viv  abil  ity for
more than 30 days un  der the stan  dard lab  o  ra  tory con  di  -
tions. For the sta tis ti cal eval u a tion, the cor re la tion co ef fi -
cient has been used.
RE SULTS  AND  DIS CUS SION
The mice treated with genistein (200 mg/kg
body weight) 24 hours be  fore ir  ra  di  a  tion dem  on  -
strated a sig nif i cant in crease in 30 day sur vival, in con -
trast to the mice treated with genistein 15 min  utes be  -
fore ir ra di a tion. The LD50/30 value for the mice treated 
with genistein (200 mg/kg) 24 hours be fore ir ra di a tion 
was 21 days while  LD50/30 value for mice treated with
genistein 15 min  utes be  fore ir  ra  di  a  tion was 14 days.
Ad di tion ally,  the  acute  tox ic ity  of  genistein  eval u ated
in  non-ir ra di ated  mice  ad min is tered  with  a  sin gle  IP
in  jec  tion of genistein of a dose of 200 mg/kg showed
no ad verse ef fects when com pared with the mice in the
con trol group. The re sults as shown in figs. 1 and 2 in -
di  cate that a sin  gle IP in  jec  tion of the genistein (200
mg/kg body weight) ad  min  is  tered 24 hours be  fore ir  -
ra di a tion of fered better pro tec tion than the one ad min -
is tered 15 min utes be fore ir ra di a tion be cause in the 24
hour group genistein is prop  erly ab  sorbed and be  -
comes able to of  fer better pro  tec  tion against ra  di  a  tion
dam age.
Op ti mum dose se lec tion. The mice ad min is tered 
with dif  fer  ent doses (100, 200, 300, and 400 mg/kg
body weight) of genistein be  fore 8 Gy gamma ir  ra  di  a  -
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as shown in the graph (fig. 1). The dose of 400 mg/kg,
on the other hand, showed the max  i  mum mor  tal  ity of
mice fol  lowed by the doses of 300 and 100 mg/kg. It
clearly es  tab  lishes that 200 mg/kg is an op  ti  mum dose
level which could have been taken into ac  count for the
ex  per  i  ments. Also, a sin  gle IP in  jec  tion of genistein of
the dose of 200 mg/kg does not show any ad verse ef fect.
Sur viv abil ity  against  ra di a tion  ex po sure. As
shown  in  fig.  2, the  mice  treated  with  genistein  
(200 mg/kg body weight) 24 hours be  fore ir  ra  di  a  tion
dem on strated a sig nif i cant in crease in 30 day sur vival,
in con  trast to the mice treated with genistein 15 min  -
utes  be fore  ir ra di a tion.  The  LD50 value for the mice
treated with genistein (200 mg/kg) 24 hours be  fore ir  -
ra  di  a  tion was 21 days while LD50 value for the mice
treated with genistein 15 min  utes be  fore ir  ra  di  a  tion
was 14 days. The re sults in di cate that a sin gle IP in jec -
tion of genistein (200 mg/kg body weight) ad  min  is  -
tered 24 hours be  fore ir  ra  di  a  tion of  fers better pro  tec  -
tion than the one ad  min  is  tered 15 min  utes be  fore
ir  ra  di  a  tion; it might have been due to the proper/com  -
plete ab  sorp  tion oc  cur  ring within 24 hours vis-à-vis
the ra  di  a  tion dam  age oc  cur  rence. As shown in tab. 1,
the lon ger sur viv abil ity (i. e. 20% for a pe riod of more
than 30 days) has been ob  served in the 24 hour group
as com  pared to the one of 15 min  utes (i. e. 20% for 22
days). Al though the radioprotective ef fect of genistein
was ev i dent in both groups, it was, how ever, of greater
mag  ni  tude in the group with a lon  ger in  ter  val prior to
ir ra di a tion  in di cat ing  thereby  an  ef fi cacy  with  lon ger
re ten tion  with  the  pos si ble  min i mum  tox ic ity,  un like
hith  erto known other radioprotective agents. The
trend lines in fig. 3 for the two genistein treated groups
show an in  creased sur  vival rate com  pared to the
genistein non-treated groups. The sta  tis  tics in tab. 2
shows how well a straight line de  scribes the data. R2
in  ter  preted as the frac  tion of the vari  abil  ity ex  plained
by the day vari  able x, shows that in all cases it is quite
close to 1, which in  di  cates that the slope of re  gres  sion
line is highly sig  nif  i  cant.
Ta ble  1.  Per cent age  sur viv abil ity  of  mice  af ter  gamma
ir ra di a tion
Hence, the pres  ent study dem  on  strates that
genistein  is  an  ef fec tive  non toxic  ra di a tion  pro tec -
tive agent against ra  di  a  tion in  duced lethality in
mice. Plans for fur  ther de  vel  op  ment of genistein to
be used as an ef  fec  tive radioprotective drug can be
ini  ti  ated. A study by Landauer et al. [11] on the
radioprotective and be  hav  ioural ef  fects of an acute
ad  min  is  tra  tion of the isoflavone genistein made on
adult CD2F1 male mice showed a sig  nif  i  cant in  -
crease in 30 day sur  vival for an  i  mals re  ceiv  ing
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Fig ure  1.  The  de ter mi na tion  of  op ti mum  dose  of
genistein vis-à-vis con  trol and sol  vent
Groups
Survivability [%]
50 40 30 20
 Control group 4 days 5 days 6 days 7 days
 Solvent (vehicle) 
jtreated group 7 days 8 days 10 days 13 days
 Genistein treated  
jgroup (15 minutes) 14 days 18 days 20 days 22 days
 Genistein treated
jgroup (24 hours) 21 days 26 days 30 days >30 days
Fig  ure 3. The lin  ear trends of the sur  viv  abil  ity curves of
mice with genistein 15 min utes and 24 hours prior to 8 Gy 
gamma  ir ra di a tion  vis-à-vis  con trol  and  ve hi cle
Fig  ure 2. The sur  viv  abil  ity curves of mice with genistein
15 min utes and 24 hours prior to 8 Gy gamma ir ra di a tion 
vis-à-vis con  trol and sol  ventgenistein doses of 25 to 400 mg/kg (p < 0.001). In
con  trast, the 30 day sur  vival rates of mice treated
with genistein 1 hour be  fore ir  ra  di  a  tion were not
sig  nif  i  cantly dif  fer  ent from the ones in the con  trol
group. Our re  sults are also in con  for  mity with their
re sults.
De vel op ments in the use of ra dio ac tive ma te ri als 
dur  ing the past de  cades have in  creased amaz  ingly,
which dis  turbs nat  u  ral bal  ance. At pres  ent, there has
not been a sin  gle ef  fec  tive radioprotective drug that
could show its ef  fi  cacy with re  spect to a lon  ger re  ten  -
tion in the body in re la tion to time of ex po sure ei ther as 
radioprotective or radiosensitive. Till now, the body
load of the drug has been first cre  ated ei  ther be  fore ir  -
ra di a tion  through  chronic  ad min is tra tion  or  the  drug
has been ad  min  is  tered just shortly be  fore or af  ter ad  -
min  is  tra  tion. The find  ings of the pres  ent work will
likely cover up such short  com  ings that ex  ist in drug
test  ing stud  ies for and against ra  di  a  tion.
The isoflavones in soy beans pos sess about 0.2% 
of the es tro genic ac tiv ity of estradiol, the prin ci ple hu -
man es  tro  gen. Soy isoflavones ac  tu  ally bind to es  tro  -
gen re  cep  tor sites in the hu  man body. Their weak es  -
tro  genic ac  tion is ac  tu  ally an antiestrogenic ef  fect, in
that the soy isoflavones pre  vent the bind  ing of the
body’s own es  tro  gen to the re  cep  tor site. This ef  fect
does not dis  rupt the nor  mal re  pro  duc  tive and fer  til  ity
func  tions of es  tro  gen, but it may coun  ter  act some of
the hor mone can cer caus ing po ten tial [12]. Onco genes 
are po  ten  tial can  cer cells that pro  duce en  zymes that
may cause cells to be come can cer ous. One of the main
en zymes  pro duced  by  onco genes  is  pro tein-ty ro sine
kinase,  an  en zyme  that  stim u lates  the  un dif fer en ti ated
growth of cells. Genistein is a very po  tent pro  -
tein-kinase in hib i tor and blocks the sig nal from the re -
cep  tors that con trol cell growth. Genistein blocks pro  -
tein-ty  ro  sine kinase and other en  zymes that trig  ger
tu  mour for  ma  tion [13]. In stud  ies of the mam  mary
glands of im  ma  ture rats, Lamartiniere [4] showed that
genistein upregulates the ex  pres  sion of the epi  der  mal
growth fac  tor re  cep  tor shortly af  ter treat  ment, which
may be re spon si ble  for  the  in creased  cell  pro lif er a tion
seen at that age. It was hy  poth  e  sized that the early
genistein ac  tion pro  motes cell  dif fer en ti a tion  that  re -
sults in a less ac tive epi der mal growth fac tor sig nal ling 
path  way in adult  hood that, in turn, sup  presses the de  -
vel  op  ment of mam  mary can  cer. Hence it can be
be lieved that early events are es sen tial for the ben e  fits
of  can cer  pro tec tion.
Zhou and Mi [14] con firmed the ra di a tion pro tec -
tion and stim  u  lat  ing haematopoietic re  cov  ery by oral
ad  min  is  tra  tions of genistein, 160 mg/kg body weight,
once daily for seven con  sec  u  tive days be  fore whole
body gamma ray ir  ra  di  a  tion of adult male BALB/c
mice. The sur  vival of ir  ra  di  ated mice pro  tected by
genistein  was  sig nif i cantly  in creased  and  sta tis ti cally
higher than that of mice pretreated with DES. The ef  -
fects of genistein on pro  mot  ing re  cov  ery of bone mar  -
row  nu cle ated  cells,  leu ko cytes  and  lym pho cytes  were
sig nif i cantly higher than those of DES. EndoCFU num -
bers in mice pretreated with genistein was 3.47-fold
higher than that in the ir  ra  di  ated con  trol group. It could
be de duced from their study that the radioprotective ac -
tion against death is in  duced by a pos  si  ble pro  cess of
en hanced re gen er a tion of the haematopoietic stem cells
due to not only strength  ened radioresistance and in  -
creased num  bers of re  mained haematopoietic cells, but
also en hanced postirradiation re pair or pro moted pro lif -
er  a  tion of the haematopoietic stem cells. Suzuki et al.
[15] found that GPx ac  ti  va  tion might be one of the im  -
por  tant char  ac  ter  is  tics of the ef  fects of genistein on
pros  tate can  cer cells. They ex  am  ined the ef  fect of
genistein on hu  man pros  tate can  cer (LNCaP and PC-3)
cells. Pro  lif  er  a  tion of both cell lines was in  hib  ited by
genistein treat  ment in a dose de  pend  ent man  ner. The
glutathione peroxidase (GPx)-1 gene ex  pres  sion level
was the most upregulated. Quan  ti  ta  tive real time poly  -
mer ase  chain  re ac tion  re vealed  sig nif i cant  el e va tion  of
tran  script lev  els of GPx-1 in both LNCaP and PC-3
cells. Upregulation of gene ex pres sion lev els ac com pa -
nied el  e  va  tion of GPx en  zyme ac  tiv  i  ties. It also in  di  -
cates the better sur vival of an i mals against ra di a tion in -
duced free rad  i  cals in the pres  ent ex  per  i  ment.
How ever,  Akimoto  and  col lab o ra tors  [16]  re -
ported the ef fect of genistein on radiosensitivity, es pe -
cially fo  cus  ing on sur  vival sig  nal transduction path  -
ways. Genistein greatly en  hanced radiosensitivity of
two hu  man esoph  a  geal squamous can  cer cell lines,
TE-1 (p53, mu tant) and TE-2 (p53, wild) by sup press -
ing  ra di a tion  in duced  ac ti va tion  of  sur vival  sig nals,
p42/p44 extracellular sig  nal reg  u  lated kinase and
AKT/PKB. Their study sug  gested that sur  vival sig  -
nals, in clud ing p42/p44 ERK and AKT/PKB, might be 
in volved  in  de ter min ing  radiosensitivity,  and
genistein would be a po  tent ther  a  peu  tic agent that had
an enhancing effect on radiation.
Nev er the less, we are of the opin ion that the treat -
ment of ma  lig  nant tu  mours through the use of ra  di  a  -
tion is of  ten lim  ited due to dam  age to non-tu  mour
cells. Dam  age to the non-tu  mour cells can ex  ceed the
ef fec tive ness  of  the  ra di a tion  ther apy.  The  dom i nant
con sid er ation  in  es tab lish ing  ra di a tion  doses  for  can -
cer ra  dio  ther  apy is the as  sess  ment of tol  er  ance of the
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Ta ble  2.  Sta tis tics  show ing  re gres sion co ef fi cient  R
2, zero
or der cor re la tion co ef fi cients R and survivability y on the 
lin  ear trend shown in fig. 3
No. Groups
Regression
coefficient
R
2
Zero order
correlation
coefficients R
Survivability y
1 Control 0.9717 –0.986 y = – 10x + 94
2 Vehicle 0.8665 –0.989 y = – 4.1671x +
+ 82.468
3 Genistein
(15 minutes) 0.9772 –0.970 y = –3.6615x +
+ 98.277
4 Genistein
(24 hours) 0.9317 –0.963 y = – 2.1958x +
+ 91.034most radiosensitive nor mal tis sue or or gan in the treat -
ment field. This as  sess  ment, to  gether with the ex  -
pected ra  di  a  tion dose re  quired to erad  i  cate a tu  mour,
de ter mines the fea si bil ity of the treat ment strat egy, and 
whether a cure or pal  li  a  tion is to be at  tempted. Of  ten,
the  max i mum  tol er a ble  doses  are  in suf fi cient to  erad i -
cate the tu  mour. Thus, the use of a radioprotective
agent would greatly in  crease the tol  er  a  ble dose, and
there  fore the pros  pects for erad  i  ca  tion of tu  mours and
treat  ment of can  cer. Genistein as a ra  dioprotective
agent may thus be use ful in elim i nat ing or re duc ing the 
se ver ity  of  del e te ri ous  cel lu lar  ef fects  in  nor mal  cells
caused  by  en vi ron men tal  or  ther a peu tic  ex po sure  to
ra di a tion, can cer ra di a tion ther apy and di ag nos tic tests 
uti liz ing  ra di a tion  where  it  might  prove  quite  del e te ri -
ous to tu  mour tis  sue (as in  di  cated by Akimoto et al.
[16] in can  cer cell line). How  ever, it war  rants fur  ther
study  and  care ful  eval u a tion.
How  ever, the genistein may be a pro  tec  tive
agent to min i mize or pre vent the dam age from so lar ra -
di a tion  ex po sure  ex pe ri enced  by  as tro nauts,  pi lots,
other flight per  son  nel, and fre  quent fli  ers. It can also
be  uti lized  in  pro tec tion  from  ac ci den tal  ra di a tion  ex -
po sure caused by nu clear power fa cil i ties, other ra di a -
tion  gen er at ing  fa cil i ties in clud ing those  for food ir ra -
di  a  tion, or by a det  o  na  tion of an atomic bomb or other
de vice that re leases ra di a tion. Also, they can be used to 
con fer pro tec tion to the per son nel in volved in clean ing 
up the areas of such radiation accidents or disposal
facilities.
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Arvind Lal BHATIJA, Axaj GAUR, Avadhe{ [ARMA
RADIOPROTEKCIJA  GENISTAJNOM
IZU^AVAWE  PRE@IVQAVAWA  MI[EVA  TRETIRANIH  IZOFLAVONOM
U radu su razmatrani radioprotektivni efekti jednokratno date doze izoflavona
genistajna (4", 5, 7-trihidroksiflavona). Mu`jaci mi{eva podvrgnuti su razli~itim dozama
genistajna (100, 200, 300 i 400 mg po kilogramu telesne mase) dvadeset~etiri ~asa pre izlagawa gama
zra~ewa od 8 Gy i utvr|eno je da doza od 200 mg po kilogramu telesne mase obezbe|uje maksimalno
pre`ivqavawe, te je u daqem eksperimentisawu bila kori{}ena kao optimalna. Petnaest minuta i 
dvadeset~etiri ~asa pre gama ozra~ivawa, doza genistajna od 0.5 ml (200 mg/kg) bila je data
intraperitonealno dvema razli~itim grupama mi{eva. Kod mi{eva tretiranih optimalnom dozom 
genistajna dvadeset~etiri ~asa pre ozra~ivawa zabele`en je zna~ajan porast pre`ivqavawa u toku
trideset dana, nasuprot mi{evima podvrgnutim genistajnu petnaest minuta pre ozra~ivawa.
Produ`eno pre`ivqavawe (20%-tno pre`ivqavawe u periodu du`em od trideset dana) prime}eno
je u grupi "24 ~asa", u pore|ewu sa grupom "15 minuta" (20%-tno pre`ivqavawe za dvadesetdva
dana). Mada su radioprotektivni efekti genistajna bili evidentni u obe grupe, domet je bio ve}i u
grupi sa du`im vremenskim intervalom, ukazaju}i na efikasnost produ`enog zadr`avawa uz
mogu}u minimalnu toksi~nost, razli~itu od drugih do sada poznatih radioprotektivnih sredstava.
Kqu~ne re~i: pre`ivqavawe, genistajn, radioprotekcija, soja, zra~ewe